MarketLens
Sign Up

Is Collegium Pharmaceutical's Diversification Strategy Paying Off

5 months ago
SHARE THIS ON:

Is Collegium Pharmaceutical's Diversification Strategy Paying Off

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News1 week ago

Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation?

McKesson's double-digit earnings growth, specialty expansion, and capital returns support its story, but a premium valuation leaves less room for error, potentially limiting upside if growth disappoin...
Stock News1 months ago

Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating

Collegium Pharmaceutical is shifting to a CNS platform, using stable pain cash flows to fund ADHD growth. The $350M cash and $300M debt AZSTARYS acquisition is expected to add $60–70M revenue in 2026 ...
Stock News1 months ago

COLO: Much Of The Upside Priced In

COLO's upside is largely priced in, limiting further gains unless a new catalyst emerges.

Breaking News

View All →

Top Headlines

View More →
Stock News1 hour ago

Seattle Times and Newsday are the latest publications to sue OpenAI and Microsoft

Stock News1 hour ago

Why Intel Stock Climbed This Week

Stock News4 hours ago

Prediction: Amazon Will Join Nvidia, Apple, and Alphabet in the $4 Trillion Club Before 2029

Stock News7 hours ago

Anthropic Could Be the Next Mega IPO: 2 Magnificent Stocks That Already Own a Piece of the AI Unicorn

Stock News8 hours ago

Why you need to own Tesla stock by next week